Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is -36.27% lower on its value in year-to-date trading and has touched a low of $17.05 and a high of $39.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARWR stock was last observed hovering at around $20.36 in the last trading session, with the day’s loss setting it -0.86%.
Currently trading at $19.50, the stock is -13.08% and -7.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.83 million and changing -4.22% at the moment leaves the stock -17.98% off its SMA200. ARWR registered -35.00% loss for a year compared to 6-month loss of -23.53%. The firm has a 50-day simple moving average (SMA 50) of $21.0652 and a 200-day simple moving average (SMA200) of $23.774426.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 4.84% gain in the last 1 month and extending the period to 3 months gives it a -6.25%, and is -11.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.57% over the week and 6.92% over the month.
Arrowhead Pharmaceuticals Inc (ARWR) has around 609 employees, a market worth around $2.43B and $3.55M in sales. Profit margin for the company is -16882.37%. Distance from 52-week low is 14.37% and -51.04% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.15%).
with sales reaching $64.14M over the same period.The EPS is expected to grow by 50.73% this year, but quarterly earnings will post 7,770.16% year-over-year. Quarterly sales are estimated to grow 1,706.15% in year-over-year returns.
373.0 institutions hold shares in Arrowhead Pharmaceuticals Inc (ARWR), with institutional investors hold 83.43% of the company’s shares. The shares outstanding are 124.38M, and float is at 116.15M with Short Float at 8.67%. Institutions hold 79.71% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.68 million shares valued at $407.61 million. The investor’s holdings represent 12.7211 of the ARWR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.21 million shares valued at $317.44 million to account for 9.9072 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 8.89 million shares representing 7.21 and valued at over $231.02 million, while FMR LLC holds 5.5256 of the shares totaling 6.81 million with a market value of $177.05 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
The most recent transaction is an insider sale by Waddill William D., the company’s Director. SEC filings show that Waddill William D. sold 3,747 shares of the company’s common stock on Dec 17 ’24 at a price of $22.04 per share for a total of $82584.0. Following the sale, the insider now owns 40378.0 shares.
Arrowhead Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 16 ’24 that Waddill William D. (Director) sold a total of 3,748 shares of the company’s common stock. The trade occurred on Dec 16 ’24 and was made at $21.90 per share for $82081.0. Following the transaction, the insider now directly holds 44125.0 shares of the ARWR stock.
Still, SEC filings show that on Dec 16 ’24, GIVEN DOUGLAS B (Director) disposed off 5,000 shares at an average price of $21.90 for $0.11 million. The insider now directly holds 124,714 shares of Arrowhead Pharmaceuticals Inc (ARWR).
